COMMUNIQUÉS West-GlobeNewswire

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
12/05/2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) [...]
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
12/05/2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to [...]
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
12/05/2025
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: [...]
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
12/05/2025
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears [...]
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
12/05/2025
Conference call will be held today, Monday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Collegium Announces $25 Million Accelerated Share Repurchase Program
12/05/2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical [...]
Registration for 2025 World Astatine Community Meeting Now Open
12/05/2025
Radiopharmaceutical experts and researchers to gather June 19-20 in New Orleans NEW ORLEANS, May 12, 2025 (GLOBE NEWSWIRE) -- The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20 [...]
ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
12/05/2025
Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human Parkinson’s disease ABLi’s [...]
Bioliberty Launches Lifehub Clinic to Transform Therapy through Soft Robotics and Gamified Exercises
12/05/2025
Oral presentation at Rehab Week will share customer data from initial system deployment EDINBURGH, United Kingdom and BOSTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Bioliberty , a medtech startup transforming the [...]
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
12/05/2025
ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion WARRINGTON [...]
Longevity Health Holdings, Inc. Announces Reverse Stock Split
12/05/2025
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc . (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has [...]
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
12/05/2025
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol [...]
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
12/05/2025
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) [...]
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
12/05/2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden [...]
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
12/05/2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate [...]
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
12/05/2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). As the biopharma industry faces increasing competition from international markets and an evolving [...]
Belite Bio to Participate in Four Upcoming Investor Conferences
12/05/2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual [...]
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
12/05/2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today [...]

Pages